(Jan 21): Johnson & Johnson’s fourth-quarter (4Q) sales beat expectations, led by strong growth for several newer cancer treatments, while it issued higher-than-expected 2026 guidance. Sales are projected to be in a range of between US$100 billion (RM405.12 billion) and US$101 billion this year — above the average of analyst estimates. It expects growth despite a deal with the White House to give discounts on some of the company’s key drugs. J&J said 4Q earnings of US$2.46 a share excluding certain items were reduced by 10 cents due to the company’s US$3.05 billion deal to buy Halda Therapeutics. Sales growth was 7.1% excluding the impact of currency translation.

Source: The Edge Markets January 21, 2026 15:42 UTC